Dupilumab for Respiratory Diseases

Phase 2

Recruiting

Research Sponsored by Scripps Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up aspirin challenge = 6 weeks after starting dupilumab/placebo. aspirin challenge day = up to 8 hours

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to study the impact of a new respiratory biologic called dupilumab on patients with Aspirin-Exacerbated Respiratory Disease (AERD) undergoing aspirin des

Who is the study for?

This trial is for adults over 18 with Aspirin-Exacerbated Respiratory Disease (AERD), diagnosed through specific tests or a history of reactions to aspirin. Participants must be on dupilumab treatment for at least 12 weeks and have a confirmed history of nasal polyposis.

What is being tested?

The study investigates the effect of dupilumab, a medication approved for certain respiratory conditions, on the process and reactions during aspirin desensitization in AERD patients. This involves observing how well patients tolerate increasing doses of aspirin.

What are the potential side effects?

Potential side effects may include hypersensitivity reactions like worsening nasal-ocular symptoms or asthma during the desensitization procedure. Dupilumab itself can cause injection site reactions, eye issues, and allergic responses.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ aspirin challenge = 6 weeks after starting dupilumab/placebo. aspirin challenge day = up to 8 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~aspirin challenge = 6 weeks after starting dupilumab/placebo. aspirin challenge day = up to 8 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and aspirin challenge = 6 weeks after starting dupilumab/placebo. aspirin challenge day = up to 8 hours for reporting.